NextCure, Inc. (NXTC): Entry into a Material Definitive Agreement
NextCure, Inc. (NXTC) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-2.1 2 tm2620428d1_ex2-1.htm EXHIBIT 2.1 Exhibit 2.1 Execution Version AGREEMENT AND PLAN OF MERGER AND REORGANIZATION among: Avere Therapeutics, Inc.; NEPTUNE MERGER SUB CORP.; NEPTUNE SECOND MERGER SUB, LLC; and NextCure, Inc. Dated as of July 14, 2026 TABLE OF CONTENTS Page
How this was made
The 30-second read
Why it matters
This is a deal-execution catalyst for NXTC, moving focus to shareholder support, regulatory approvals, and closing conditions, plus any governance or compensatory changes for officers/directors.
Market read
Deal-signing typically triggers repricing toward deal value and increases sensitivity to approval and termination-risk headlines.
What to watch
Traders will need the missing deal economics (consideration, CVR terms, termination fees, and timing) and any officer/director changes referenced in Item 5.02 to gauge true risk-reward.
Background
The 8-K reports entry into a material definitive agreement and includes an Agreement and Plan of Merger and Reorganization among NextCure (Parent) and Avere Therapeutics (Company) with two merger subsidiaries.
Ticker impact
NextCure entered a material definitive merger agreement, with its company merging into Neptune Merger Subs as part of an integrated transaction.
Near-term volatility likely around deal terms, vote/approval milestones, and any deal-termination conditions; direction depends on implied valuation versus current expectations.
An 8-K Exhibit 2.1 confirms a signed agreement and merger structure, which typically drives repricing toward deal value, but the excerpt provides no consideration details or timing/conditions.
Market effects
Signals ongoing consolidation in biotech, which can affect sentiment for small-cap oncology/biopharma M&A comps.
Primarily US small-cap biotech sentiment; limited direct regional spillover from the excerpt alone.
Low global relevance unless the acquirer’s footprint or regulatory path is material, which is not specified in the provided text.
Counterpoint
A signed merger agreement does not guarantee closing; termination fees, regulatory hurdles, or financing conditions can still derail the deal and pressure the stock.
Key entities
- public_companyNextCure, Inc.
Subject of the 8-K, reported as the Parent in the merger agreement.
- public_companyAvere Therapeutics, Inc.
Named as the Company to be merged into Neptune Second Merger Sub as part of the integrated transaction.
- merger_subNeptune Merger Sub Corp.
Wholly owned subsidiary of Parent involved in the first-step merger.
- merger_subNeptune Second Merger Sub, LLC
Wholly owned subsidiary of Parent and surviving entity of the second-step merger.
